{"id":64738,"date":"2026-05-08T15:10:29","date_gmt":"2026-05-08T07:10:29","guid":{"rendered":"https:\/\/flcube.com\/?p=64738"},"modified":"2026-05-08T15:10:30","modified_gmt":"2026-05-08T07:10:30","slug":"eli-lilly-reports-56-revenue-surge-in-q1-2026-driven-by-mounjaro-and-zepbound-dominance-raises-full-year-guidance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64738","title":{"rendered":"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance"},"content":{"rendered":"\n<p><strong>Eli Lilly &amp; Co.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced <strong>first-quarter 2026 global sales of $19.8 billion<\/strong>, representing a <strong>56% year-over-year increase<\/strong> in constant currency terms, fueled by unprecedented demand for its <strong>GLP-1 franchise<\/strong> led by <strong>Mounjaro<\/strong> and <strong>Zepbound (tirzepatide)<\/strong>. The company&#8217;s exceptional performance prompted a <strong>$2 billion upward revision to full-year revenue guidance<\/strong>, supported by the recent <strong>FDA approval of Foundayo<\/strong>, which significantly expands the addressable population for GLP-1 therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><th>Key Drivers<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Sales<\/strong><\/td><td>$19.8 billion<\/td><td>+56%<\/td><td>GLP-1 franchise, immunology\/oncology growth<\/td><\/tr><tr><td><strong>Volume Impact<\/strong><\/td><td>+65%<\/td><td>Primary growth driver<\/td><td>Exceptional demand across key products<\/td><\/tr><tr><td><strong>Price Impact<\/strong><\/td><td>-13%<\/td><td>Offset by volume surge<\/td><td>NRDL inclusion, competitive pricing<\/td><\/tr><tr><td><strong>Key Product Revenue<\/strong><\/td><td>$13.4 billion<\/td><td>Substantial increase<\/td><td>Tirzepatide dominance, specialty portfolio<\/td><\/tr><tr><td><strong>Immunology\/Oncology\/Neuroscience<\/strong><\/td><td>Significant growth<\/td><td>+160%<\/td><td>New product launches, market expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-product-performance-analysis\">Key Product Performance Analysis<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-glp-1-franchise-market-transformation\">GLP-1 Franchise \u2013 Market Transformation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mounjaro (tirzepatide)<\/strong>: $8.662 billion (+125% YOY) \u2013 establishing dominant position in diabetes market<\/li>\n\n\n\n<li><strong>Zepbound (tirzepatide)<\/strong>: $4.16 billion (+80% YOY) \u2013 rapid obesity treatment adoption exceeding expectations<\/li>\n\n\n\n<li><strong>Foundayo<\/strong>: Recently FDA-approved, expanding GLP-1 eligible population significantly<\/li>\n\n\n\n<li><strong>Market Impact<\/strong>: Combined $12.8 billion quarterly revenue demonstrates category leadership<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-specialty-portfolio-accelerating-growth\">Specialty Portfolio \u2013 Accelerating Growth<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Jaypirca (pirtobrutinib)<\/strong>: $165 million (+79% YOY) \u2013 strong oncology momentum in chronic lymphocytic leukemia<\/li>\n\n\n\n<li><strong>Ebglyss (lebrikizumab)<\/strong>: $145 million (+141% YOY) \u2013 rapid atopic dermatitis market penetration<\/li>\n\n\n\n<li><strong>Kisunla (donanemab)<\/strong>: $124 million \u2013 Alzheimer&#8217;s disease treatment gaining initial traction<\/li>\n\n\n\n<li><strong>Omvoh (mirikizumab)<\/strong>: $80 million (+115% YOY) \u2013 ulcerative colitis indication showing strong uptake<\/li>\n\n\n\n<li><strong>Inluriyo (imlunestrant)<\/strong>: $35 million \u2013 early-stage breast cancer therapy establishing market presence<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-geographic-performance-breakdown\">Geographic Performance Breakdown<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-united-states-core-market-strength\">United States \u2013 Core Market Strength<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue<\/strong>: $12.1 billion (+43% YOY)<\/li>\n\n\n\n<li><strong>Volume Growth<\/strong>: +49% driven by GLP-1 demand<\/li>\n\n\n\n<li><strong>Price Impact<\/strong>: -7% primarily from Zepbound and Taltz pricing dynamics<\/li>\n\n\n\n<li><strong>Market Leadership<\/strong>: Maintaining premium positioning despite competitive pressures<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-international-markets-exceptional-expansion\">International Markets \u2013 Exceptional Expansion<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total International<\/strong>: $7.7 billion (+81% YOY)<\/li>\n\n\n\n<li><strong>Volume Surge<\/strong>: +95% reflecting global GLP-1 adoption<\/li>\n\n\n\n<li><strong>Price Decline<\/strong>: -25% mainly due to <strong>Mounjaro&#8217;s inclusion in China&#8217;s National Reimbursement Drug List (NRDL)<\/strong><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-regional-highlights\">Regional Highlights<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Europe<\/strong>: $3.646 billion (+53% YOY) \u2013 strong regulatory acceptance and market access<\/li>\n\n\n\n<li><strong>China<\/strong>: $693 million (+54% YOY) \u2013 NRDL inclusion driving volume despite price reduction<\/li>\n\n\n\n<li><strong>Japan<\/strong>: $571 million (+42% YOY) \u2013 established market with growing specialty medicine adoption<\/li>\n\n\n\n<li><strong>Other Markets<\/strong>: $2.771 billion (+178% YOY) \u2013 emerging markets showing explosive growth potential<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-business-developments\">Strategic Business Developments<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pipeline-and-regulatory-milestones\">Pipeline and Regulatory Milestones<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Foundayo Approval<\/strong>: FDA clearance significantly expands GLP-1 treatable population<\/li>\n\n\n\n<li><strong>Guidance Raise<\/strong>: $2 billion upward revision reflects confidence in sustained demand trajectory<\/li>\n\n\n\n<li><strong>Manufacturing Investment<\/strong>: Capacity expansion supporting supply chain reliability<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-acquisition-strategy\">Acquisition Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Orna Therapeutics<\/strong>: mRNA technology platform enhancing next-generation therapeutic capabilities<\/li>\n\n\n\n<li><strong>Centessa Pharmaceuticals plc<\/strong>: Targeted protein degradation expertise strengthening oncology pipeline<\/li>\n\n\n\n<li><strong>Kelonia Therapeutics<\/strong>: Novel modalities in autoimmune and inflammatory diseases<\/li>\n\n\n\n<li><strong>Ajax Therapeutics<\/strong>: Early-stage innovation complementing existing R&amp;D portfolio<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-and-competitive-positioning\">Market Context and Competitive Positioning<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-glp-1-market-dynamics\">GLP-1 Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Category Leadership<\/strong>: Tirzepatide&#8217;s dual GIP\/GLP-1 mechanism providing clinical differentiation<\/li>\n\n\n\n<li><strong>Supply Constraints<\/strong>: Managing unprecedented demand while maintaining quality standards<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Balancing volume growth with sustainable margin structure<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-therapeutic-area-expansion\">Therapeutic Area Expansion<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immunology<\/strong>: Multiple assets addressing unmet needs in atopic dermatitis, ulcerative colitis<\/li>\n\n\n\n<li><strong>Oncology<\/strong>: Targeted therapies showing strong clinical profiles in hematologic malignancies<\/li>\n\n\n\n<li><strong>Neuroscience<\/strong>: Alzheimer&#8217;s disease treatment representing significant market opportunity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-indicators\">Forward-Looking Indicators<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-full-year-expectations\">Full-Year Expectations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Guidance<\/strong>: Raised by $2 billion reflecting strong Q1 performance and pipeline catalysts<\/li>\n\n\n\n<li><strong>GLP-1 Franchise<\/strong>: Expected to maintain dominant market share through clinical superiority<\/li>\n\n\n\n<li><strong>Specialty Portfolio<\/strong>: Continued acceleration across immunology, oncology, and neuroscience<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-manufacturing-and-supply-chain\">Manufacturing and Supply Chain<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capacity Expansion<\/strong>: Multi-billion dollar investments supporting long-term demand requirements<\/li>\n\n\n\n<li><strong>Global Distribution<\/strong>: Enhanced logistics network ensuring product availability worldwide<\/li>\n\n\n\n<li><strong>Quality Assurance<\/strong>: Maintaining highest standards despite rapid scale-up<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-implications\">Investment Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stock Performance<\/strong>: LLY closed at $845.20 on May 7, 2026; trading at premium valuation reflecting growth trajectory<\/li>\n\n\n\n<li><strong>Dividend Policy<\/strong>: Sustainable dividend growth supported by strong cash generation<\/li>\n\n\n\n<li><strong>Pipeline Value<\/strong>: Multiple late-stage assets providing long-term revenue visibility<\/li>\n\n\n\n<li><strong>Strategic Positioning<\/strong>: Industry-leading position in high-growth therapeutic categories<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Eli Lilly&#8217;s financial performance, product sales, regulatory approvals, and strategic acquisitions. Actual results may differ due to competitive pressures, manufacturing challenges, regulatory developments, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/Q1-2026-Press-Release.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Q1 2026 Press Release.\"><\/object><a id=\"wp-block-file--media-57b6375a-fea6-47b1-87b0-927890ebe2ac\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/Q1-2026-Press-Release.pdf\">Q1 2026 Press Release<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/Q1-2026-Press-Release.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-57b6375a-fea6-47b1-87b0-927890ebe2ac\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly &amp; Co. (NYSE: LLY) announced first-quarter 2026 global sales of $19.8 billion, representing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64741,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[199,27,911],"class_list":["post-64738","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-eli-lilly","tag-finanical-reports","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly &amp; Co. (NYSE: LLY) announced first-quarter 2026 global sales of $19.8 billion, representing a 56% year-over-year increase in constant currency terms, fueled by unprecedented demand for its GLP-1 franchise led by Mounjaro and Zepbound (tirzepatide). The company&#039;s exceptional performance prompted a $2 billion upward revision to full-year revenue guidance, supported by the recent FDA approval of Foundayo, which significantly expands the addressable population for GLP-1 therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64738\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly &amp; Co. (NYSE: LLY) announced first-quarter 2026 global sales of $19.8 billion, representing a 56% year-over-year increase in constant currency terms, fueled by unprecedented demand for its GLP-1 franchise led by Mounjaro and Zepbound (tirzepatide). The company&#039;s exceptional performance prompted a $2 billion upward revision to full-year revenue guidance, supported by the recent FDA approval of Foundayo, which significantly expands the addressable population for GLP-1 therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64738\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T07:10:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T07:10:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0805.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64738#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64738\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance\",\"datePublished\":\"2026-05-08T07:10:29+00:00\",\"dateModified\":\"2026-05-08T07:10:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64738\"},\"wordCount\":642,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64738#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0805.webp\",\"keywords\":[\"Eli Lilly\",\"Finanical Reports\",\"NYSE: LLY\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64738#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64738\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64738\",\"name\":\"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64738#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64738#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0805.webp\",\"datePublished\":\"2026-05-08T07:10:29+00:00\",\"dateModified\":\"2026-05-08T07:10:30+00:00\",\"description\":\"Eli Lilly & Co. (NYSE: LLY) announced first-quarter 2026 global sales of $19.8 billion, representing a 56% year-over-year increase in constant currency terms, fueled by unprecedented demand for its GLP-1 franchise led by Mounjaro and Zepbound (tirzepatide). The company's exceptional performance prompted a $2 billion upward revision to full-year revenue guidance, supported by the recent FDA approval of Foundayo, which significantly expands the addressable population for GLP-1 therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64738#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64738\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64738#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0805.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0805.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64738#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly & Co. (NYSE: LLY) announced first-quarter 2026 global sales of $19.8 billion, representing a 56% year-over-year increase in constant currency terms, fueled by unprecedented demand for its GLP-1 franchise led by Mounjaro and Zepbound (tirzepatide). The company's exceptional performance prompted a $2 billion upward revision to full-year revenue guidance, supported by the recent FDA approval of Foundayo, which significantly expands the addressable population for GLP-1 therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64738","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance","og_description":"Eli Lilly & Co. (NYSE: LLY) announced first-quarter 2026 global sales of $19.8 billion, representing a 56% year-over-year increase in constant currency terms, fueled by unprecedented demand for its GLP-1 franchise led by Mounjaro and Zepbound (tirzepatide). The company's exceptional performance prompted a $2 billion upward revision to full-year revenue guidance, supported by the recent FDA approval of Foundayo, which significantly expands the addressable population for GLP-1 therapies.","og_url":"https:\/\/flcube.com\/?p=64738","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-08T07:10:29+00:00","article_modified_time":"2026-05-08T07:10:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0805.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64738#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64738"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance","datePublished":"2026-05-08T07:10:29+00:00","dateModified":"2026-05-08T07:10:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64738"},"wordCount":642,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64738#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0805.webp","keywords":["Eli Lilly","Finanical Reports","NYSE: LLY"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64738#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64738","url":"https:\/\/flcube.com\/?p=64738","name":"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64738#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64738#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0805.webp","datePublished":"2026-05-08T07:10:29+00:00","dateModified":"2026-05-08T07:10:30+00:00","description":"Eli Lilly & Co. (NYSE: LLY) announced first-quarter 2026 global sales of $19.8 billion, representing a 56% year-over-year increase in constant currency terms, fueled by unprecedented demand for its GLP-1 franchise led by Mounjaro and Zepbound (tirzepatide). The company's exceptional performance prompted a $2 billion upward revision to full-year revenue guidance, supported by the recent FDA approval of Foundayo, which significantly expands the addressable population for GLP-1 therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64738#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64738"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64738#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0805.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0805.webp","width":1080,"height":608,"caption":"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64738#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0805.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64738"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64738\/revisions"}],"predecessor-version":[{"id":64742,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64738\/revisions\/64742"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64741"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}